Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345773 | 0.96 | NPC1 (0.56) | NPC1RAB9APTPN1PTPN2PTPN6 | |
| SCHEMBL346486 | 0.91 | NPC1 (0.58) | NPC1RAB9APTPN1PTPN2PTPN6 | |
| SCHEMBL345519 | 0.87 | NPC1 (0.58) | NPC1RAB9APTPN1PTPN2PTPN6 | |
| SCHEMBL346828 | 0.79 | NPC1 (0.49) | NPC1RAB9APTPN1 | |
| SCHEMBL438223 | 0.78 | NPC1 (0.41) | NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL31058077 | 0.76 | NAMPT (0.59) | NPC1RAB9APTPN1PTPN2PTPN6 | |
| SCHEMBL20137661 | 0.74 | TSHR (0.52) | PTPN1PTPN2PTPN6ALDH1A1GPR119 | |
| SCHEMBL354658 | 0.74 | NPC1 (0.42) | NPC1RAB9AALDH1A1GPR119KMT2A | |
| SCHEMBL346770 | 0.73 | NPC1 (0.38) | NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL31058055 | 0.73 | PTPN2 (0.43) | NPC1RAB9APTPN1PTPN2PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | NPC1 2892/4885RAB9A 1979/4885PTPN1 3390/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | NPC1 3030/4885RAB9A 939/4885PTPN1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.